Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 488 Adverse Events, 48 Deaths Attributed to Alteplase
November 13, 2006
- FPMAJ, JPMA Call For Revision of Transfer Price Taxation System
November 13, 2006
- SURVEY 2 articles
November 13, 2006
- Coordination Essential for More Efficient Clinical Trials: JCROA Symposium
November 13, 2006
- Guerbet to Enhance Its Visibility in Japan
November 13, 2006
- REGULATORY NEWS IN BRIEF
November 13, 2006
- Korosho's Study Group on "Device Lag" Holds 1st Meeting
November 13, 2006
- TOPICS Diet Members with Cancer to Set Up Society
November 13, 2006
- Terumo: Double-digit Growth in Consolidated Sales, Profits
November 13, 2006
- Baxter to Provide Plasma/Albumin-Free Factor VIII to Hemophilia A Patients in Japan
November 13, 2006
- MEDICAL DEVICE NEWS IN BRIEF
November 13, 2006
- OPINION
November 6, 2006
- MD Devices, Diagnostics at Chuikyo
November 6, 2006
- NEW PRODUCTS
November 6, 2006
- MEDICAL DEVICE NEWS IN BRIEF
November 6, 2006
- Signa HDe, BrightSpeed Granted Good Design Awards: GE Yokogawa Medical System
November 6, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 6, 2006
- Call for Withdrawal from JPA Gathers Momentum among JACDS Members
November 6, 2006
- SEMINAR
November 6, 2006
- Import of Fludara Tab Recommended for Approval
November 6, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…